NEW YORK (CNNMoney.com) -- Goldman Sachs CEO Lloyd Blankfein will testify Tuesday that his firm didn't mislead investors and didn't bet against the housing market, according to his opening remarks released Monday.
"We didn't have a massive short against the housing market and we certainly did not bet against our clients," Blankfein said in remarks prepared for Tuesday's testimony, which he will give before the Permanent Senate Subcommittee on Investigations.
Goldman Sachs (GS, Fortune 500) is accused by the Securities and Exchange Commission of failing to tell investors that hedge fund Paulson & Co. helped select securities for a portfolio that it was also betting against.
"It was one of the worst days in my professional life," Blankfein said in the testimony about the SEC's charges, made April 16. "If our clients believe that we don't deserve their trust, we cannot survive."
While denying the allegations, Blankfein acknowledged a lack of transparency in derivative markets and the failure of financial institutions to properly warn the public about over-lending and cheap credit at the brink of the economic crisis.
"What we and other banks, rating agencies and regulators failed to do was sound the alarm that there was too much lending and too much leverage in the system -- that credit had become too cheap," he said.
In a push for greater transparency, Blankfein said in his testimony that Goldman supports financial regulatory reform as well as stricter controls for derivatives.
Blankfein also said Goldman Sachs did suffer during the financial crisis, losing $1.2 billion from activities in the residential housing market.
Six other current and former Goldman executives will join Blankfein to testify before the Senate Subcommittee on Tuesday as part of the panel's ongoing investigation into the causes of the recent financial crisis.
Irish drug maker Mallinckrodt will have to pay a $100 million fine and allow one of its competitors to produce a life-saving medication used to treat infants. The company hiked the price of the drug from $40 per vial to more than $34,000 per vial over the course of about 15 years. More
Economists expect official figures to show that China's economy maintained its "uncanny stability" by growing at 6.7% for a fourth consecutive quarter. More
In 1998, Ntsiki Biyela won a scholarship to study wine making. Now she's about to launch her own brand. More
Navient, formerly part of Sallie Mae, was sued by the CFPB Wednesday for allegedly cheating borrowers out of repayment rights. More